Condition: Interstitial Lung Disease · Common Variable Immunodeficiency · Sponsor: Children's Hospital Medical Center, Cincinnati
There is no standard of care therapy for patients with granulomatous-lymphocytic interstitial lung disease (GLILD) seen in common variable immunodeficiency (CVID). Abatacept has recently looked promising for the treatment of patients with complex CVID. This study is a multi-site, phase II, randomized, blinded/placebo-controlled clinical trial in pediatric and adult subjects to determine the efficacy of abatacept compared to placebo for treatment of subjects with GLILD in the context of CVID. Funding Source - FDA OOPD
This description comes directly from the study's public registry record.
Michael Jordan · 513-803-9063 · Michael.Jordan.@cchmc.org
Always discuss trial participation with your own doctor first.
| University of California, San Francisco | San Francisco, California, United States | Recruiting |
| University of South Florida | Tampa, Florida, United States | Recruiting |
| Lahey Hospital and Medical Center | Burlington, Massachusetts, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| Duke University Health System | Durham, North Carolina, United States | Recruiting |
| Cincinnati Children's Hospital Medical Center | Cincinnati, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04925375